Recherchiere Firmenbekanntmachungen und finanzielle Kennzahlen
EU-Förderung (27,9 Mio. €): EUbOPEN: Aktivieren und Entsperren der Biologie im OPEN Hor01.05.2020 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Auf einen Blick
Text
EUbOPEN: Aktivieren und Entsperren der Biologie im OPEN
The EUbOPEN partnership of excellence will aim to generate the largest freely available set of high-quality chemical inhibitors for human proteins. These compounds will include chemical probes for solute carriers (SLCs), E3-ubiquitin ligases (E3s) and other proteins, and a chemogenomic library (CGL) of 3000-5000 compounds covering one third of the druggable genome. All compounds in the sets will be comprehensively characterised defining their selectivity, potency and cellular activity. The compounds will be annotated with a series of established and novel biochemical and cell-based assays, including many derived from primary patient cells. Diseases of particular focus will be inflammatory bowel disease, cancer and neurodegeneration. EUbOPEN partners have proven track records leading large international open science projects, developing unencumbered key reagents, and exploring new target areas. A strong commitment to open data and open science will accelerate the dissemination of knowledge and reagents as well as mitigate ethical issues that might arise by working with patient-derived cells. EUbOPEN will partner extensively with other large projects (e.g. ReSOLUTE, Illuminating the Druggable Genome) to minimize duplication of effort and to maximize global coordination. EUbOPEN will provide via the EFPIA partners the public access to industry’s deep medicinal chemistry skills. Sustainability of the project’s resources will be ensured through already established partnerships with chemical vendors and cheminformatics/database providers, which will ensure the long-term availability of the new chemical tool sets, all associated profiling data and established protocols. The EUbOPEN project will form the foundation for future efforts to generate chemical modulators for the entire druggable genome and will develop new technologies significantly shortening hit and lead identification processes.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| Academisch Ziekenhuis Leiden | 984.901 € |
| BAYER AG | 0,00 € |
| 0,00 € | |
| CHEMOTHERAPEUTISCHES FORSCHUNGSINSTITUT GEORG-SPEYER-HAUS STIFTUNG | 737.754 € |
| Diamond Light Source Ltd. | 0,00 € |
| EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH | 984.901 € |
| 331.990 € | |
| FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG e. V. | 562.400 € |
| Institut de Recherches Servier | 0,00 € |
| JOHANN WOLFGANG GOETHE-UNIVERSITAET FRANKFURT AM MAIN | 7.171.503 € |
| Karolinska Institutet | 7.909.929 € |
| Kungliga Tekniska Hoegskolan | 0,00 € |
| LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN | 12.500,00 € |
| Ontario Institute for Cancer Research | 0,00 € |
| Pfizer Ltd. | 0,00 € |
| Relay ML Discovery LLC | 0,00 € |
| 0,00 € | |
| Structural Genomics Consortium LBG | 102.059 € |
| TAKEDA PHARMACEUTICALS INTERNATIONAL AG | 0,00 € |
| THE Governing Council OF THE University OF Toronto | 0,00 € |
| 0,00 € | |
| The Chancellor, Masters and Scholars of the University of Oxford | 8.152.162 € |
| University of Dundee | 984.901 € |
Quelle: https://cordis.europa.eu/project/id/875510
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.
Die Visualisierungen zu "Academisch Ziekenhuis Leiden - EU-Förderung (27,9 Mio. €): EUbOPEN: Aktivieren und Entsperren der Biologie im OPEN"
werden von
North Data
zur Weiterverwendung unter einer
Creative Commons Lizenz
zur Verfügung gestellt.
